- Home
- MED vs INZY Comparison
MED vs INZY Comparison
Compare MED & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- INZY
- Stock Information
- Founded
- MED 1980
- INZY 2015
- Country
- MED United States
- INZY United States
- Employees
- MED N/A
- INZY N/A
- Industry
- MED Packaged Foods
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- MED Consumer Staples
- INZY Health Care
- Exchange
- MED Nasdaq
- INZY Nasdaq
- Market Cap
- MED 201.4M
- INZY 165.1M
- IPO Year
- MED N/A
- INZY 2020
- Fundamental
- Price
- MED $16.88
- INZY $2.94
- Analyst Decision
- MED Hold
- INZY Strong Buy
- Analyst Count
- MED 1
- INZY 7
- Target Price
- MED $17.00
- INZY $16.14
- AVG Volume (30 Days)
- MED 246.0K
- INZY 920.5K
- Earning Date
- MED 11-04-2024
- INZY 11-05-2024
- Dividend Yield
- MED N/A
- INZY N/A
- EPS Growth
- MED N/A
- INZY N/A
- EPS
- MED 0.67
- INZY N/A
- Revenue
- MED $674,475,000.00
- INZY N/A
- Revenue This Year
- MED N/A
- INZY N/A
- Revenue Next Year
- MED N/A
- INZY N/A
- P/E Ratio
- MED $25.42
- INZY N/A
- Revenue Growth
- MED N/A
- INZY N/A
- 52 Week Low
- MED $16.73
- INZY $2.39
- 52 Week High
- MED $70.58
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- MED 36.65
- INZY 39.38
- Support Level
- MED $17.69
- INZY $2.65
- Resistance Level
- MED $21.98
- INZY $3.28
- Average True Range (ATR)
- MED 1.17
- INZY 0.25
- MACD
- MED -0.39
- INZY 0.07
- Stochastic Oscillator
- MED 2.90
- INZY 39.07
About MED MEDIFAST INC
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.